AGP Executive Report
Last update: 8 hours agoEU Health Policy: The European Commission approved MSD’s Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin) for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, with the first PD-1 inhibitor + antibody-drug conjugate option for this group across EU states plus Iceland, Liechtenstein and Norway. EU Justice & Security: Brussels proposed stronger EU-wide mandates for Europol and Eurojust, updates to the European Investigation Order, and changes to data rules for Union bodies to speed cross-border serious-crime and terrorism cases. Liechtenstein in the Regulatory Spotlight: Bitcoin Suisse secured a MiCAR Crypto Asset Service Provider licence in Liechtenstein, giving it a regulated route to expand services across selected EEA markets. Cross-Border Migration Debate (Switzerland): A Swiss parliamentary push would add “security” and “infrastructure” style fees for foreign residents, raising free-movement concerns for EU/EFTA nationals including Liechtenstein citizens. Public Safety: Switzerland raised heatwave warnings to level 4 across large areas, including parts of the Rhine Valley and Ticino.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.